Single-dose pharmacokinetics of telmisartan oral solution and effect of feeding in dogs

Allison G. Bechtel, Jennifer M. Reinhart, Zhong Li

Research output: Contribution to journalArticlepeer-review


Telmisartan is an angiotensin II receptor blocker that has great potential to improve the treatment of hypertension, proteinuria, and cardiovascular disease in dogs. A feline-approved telmisartan oral solution (TOS) is available, but this formulation has not been evaluated in dogs. The aims of this study were to establish the pharmacokinetics of telmisartan administered as TOS and determine the effect of feeding on drug absorption in dogs. In a cross-over design, seven healthy dogs received 1 mg/kg telmisartan orally as TOS with or without food and underwent serial measurement of plasma telmisartan concentrations over 24 h. Bioequivalence of TOS administered with vs. without food was assessed by the 90% confidence interval method for maximum concentration (Cmax), and the observed and extrapolated areas under the curve (AUC0–t and AUC0–∞). The mean ratios of these parameters were 0.97 (CI 0.74–1.27), 0.92 (0.81–1.03), and 0.90 (0.82–1.00), respectively. Feeding methods were not bioequivalent based on Cmax due to interindividual variation. These results suggest that TOS can be given to dogs with or without food but should be administered in the same way consistently. Additional pharmacokinetic and pharmacodynamic studies are warranted to confirm this recommendation and establish the therapeutic targets for telmisartan in dogs.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalJournal of Veterinary Pharmacology and Therapeutics
Issue number1
StatePublished - Jan 2023


  • angiotensin II receptor blocker
  • dog
  • hypertension
  • pharmacokinetics
  • proteinuria

ASJC Scopus subject areas

  • General Veterinary
  • Pharmacology


Dive into the research topics of 'Single-dose pharmacokinetics of telmisartan oral solution and effect of feeding in dogs'. Together they form a unique fingerprint.

Cite this